Q2 earnings season for large-cap pharmaceutical stocks is set to kick off when Eli Lilly and Co LLY reports results on Thursday morning. Piper Jaffray analyst Richard Purkiss released a report this week outlining what the market can expect once the action begins on Thursday.
Peak Forex Pressure?
Pfizer’s leading international exposure is followed by Merck & Co, Inc. MRK at 58 percent, Lilly at 53 percent and Bristol-Myers Squibb Co BMY at 49 percent. AbbVie Inc ABBV will face the least forex headwinds, with only 47 percent of its business taking place internationally.
Exclusivity Loss
Predictions
- Lilly: Piper Jaffray’s forecast is $0.01 above consensus earnings per share (EPS) and about $45 million above consensus revenue estimates.
- Bristol-Myers: Piper Jaffray is calling for a 6 percent revenue beat and EPS of $0.39, $0.03 above consensus.
- AbbVie: Piper Jaffray is mostly in-line with consensus on AbbVie, calling for EPS of $1.06 (versus consensus of $1.06) and revenue of $5.5 billion (versus consensus of $5.6 billion) for the quarter.
- Merck: Piper Jaffray’s Q2 revenue estimates of $9.7 billion are in-line with consensus, but the firm sees a $0.02 EPS beat on stronger-than-consensus margins.
- Pfizer: Piper Jaffray sees a miss on the horizon for Pfizer and is calling for EPS of $0.50 (versus consensus of $0.51) on revenue of $11.1 billion (versus consensus of $11.4 billion).
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.